Kivu Bioscience Kivu Bioscience Kivu Bioscience

Kivu Bioscience

Pioneering next-generation antibody-drug conjugates (ADC's) in oncology

Kivu Bioscience is pioneering next-generation antibody-drug conjugates (ADCs) in oncology. The company’s linker-payload technology delivers enhanced safety and efficacy, minimizing off-target effects to improve patient outcomes. With multiple ADC programs in development and a team of industry veterans, Kivu is advancing its two assets to clinical trials and achieve a robust clinical proof of concept. The company is headquartered in Delaware.

Life Sciences

visit website

Investment  details

Entry

2024

Staff

Location

USA

I am grateful to be working with a top-tier group of investors and drug developers who are inspired by patients, fueled by data to rapidly develop transformative cancer medicines

Mohit Trikha, Ph.D.

President & COO

Partnership Gimv

The ambition of Kivu Bioscience holds great potential to significantly enhance patient outcomes in the future. We are excited to work alongside co-investors and the management team to join forces and make Kivu a leading ADC company while bringing new therapeutic solutions to the market.